Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, treatment with XTANDI (enzalutamide) plus ADT was associated with a 66% probability of survival at five years compared to 53% probability of survival with placebo plus ADT XTANDI (enzalutamide) is the first and only androgen receptor... Read More

NEW YORK / May 19, 2025 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently undergoing several clinical trials in China for non-small cell lung... Read More

Delivers Robust Earnings Performance, Successfully Navigating a Dynamic Environment Made Significant Progress Strengthening the R&D Organization On Track to Exceed Net Cost Savings Targets NEW YORK / Apr 29, 2025 / Business Wire / Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2025 and reaffirmed its 2025 financial guidance (1) . EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer:... Read More

Pivotal Phase 3 CREST trial results show a 32% reduction in the risk of disease-related events, including high-grade disease recurrence or progression, with sasanlimab in combination with standard of care (SOC) Bacillus Calmette-Guérin (BCG) regimen compared to SOC alone Sasanlimab, a subcutaneously administered PD-1 inhibitor, in combination with BCG represents the first potential treatment advancement for BCG-naïve,... Read More

Board of Directors approves quarterly cash dividend of $0.43 per share NEW YORK / Apr 23, 2025 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2025 dividend on the company’s common stock, payable June 13, 2025, to holders of the Common Stock of record at the close of business on May 9, 2025. The second-quarter 2025 cash dividend will be the 346th... Read More

More than 60 abstracts, including 15 oral and rapid oral presentations, highlight advancements across Pfizer’s industry-leading Oncology portfolio ASCO press program to feature overall survival and progression-free survival data for BRAFTOVI ® (encorafenib) combination regimen in first-line BRAF V600E-mutant metastatic colorectal cancer and progression-free survival data from VERITAC-2 study of vepdegestrant in metastatic... Read More

Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74 NEW YORK / Apr 16, 2025 / Business Wire / Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults... Read More

NEW YORK / Apr 14, 2025 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated for chronic weight management. Pfizer’s dose-optimization studies of once-daily formulations of danuglipron ( NCT06567327 and NCT06568731 ) met key pharmacokinetic objectives and confirmed... Read More

NEW YORK / Apr 10, 2025 / Business Wire / Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual 2025 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 24, 2025. Pfizer has designed the virtual Annual Meeting to ensure that its shareholders who participate will be afforded comparable rights and opportunities to participate as they would at an... Read More

ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 NEW YORK / Apr 01, 2025 / Business Wire / Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO ® , the company’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, to extend the indication to include... Read More

MONTRÉAL , March 25, 2025 /CNW/ - ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce that APRETUDE (cabotegravir tablets and extended release injectable suspension) is now covered under the federal Non-Insured Health Benefits (NIHB) Program for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually... Read More

NEW YORK / Mar 18, 2025 / Business Wire / Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, April 29, 2025. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2025 Performance Report, to be issued that morning. To view and listen to the... Read More

NEW YORK / Feb 24, 2025 / Business Wire / Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 45 th Annual Health Care Conference on Monday, March 3, 2025 at 10:30 a.m. Eastern Standard Time. To listen to the webcast, visit our web site at www.pfizer.com/investors . Information on accessing and... Read More

TALZENNA + XTANDI is the first PARP inhibitor plus ARPI combination to demonstrate statistically significant and clinically meaningful improvement in overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) regardless of HRR mutation status TALZENNA + XTANDI improved median OS by almost 9 months in unselected patients (Cohort 1) and by 14 months in patients selected for HRR mutations... Read More

MONTRÉAL , Feb. 13, 2025 /CNW/ - ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for APRETUDE (cabotegravir tablets and extended release injectable suspension) for pre-exposure prophylaxis (PrEP) to reduce the risk... Read More

Approval is based on positive data from the Phase 3 ECHELON-3 trial, which demonstrated ADCETRIS regimen reduced the risk of death by 37%, a statistically significant, clinically meaningful improvement in overall survival (OS), compared to lenalidomide and rituximab plus placebo ECHELON-3 is the first Phase 3 trial to demonstrate OS advantage over lenalidomide and rituximab plus placebo for patients with at least 2 prior... Read More

Enfortumab vedotin plus pembrolizumab continues to demonstrate superior efficacy versus chemotherapy in a broad population, reinforcing the combination as standard of care in first-line treatment of la/mUC At nearly 30 months of follow-up in the Phase 3 EV-302 trial, the combination doubled median overall survival and progression-free survival compared to chemotherapy, with no new safety signals identified NEW YORK & TOKYO /... Read More

Full-Year 2024 Revenues of $63.6 Billion, Reflecting 7% Year-over-Year Operational Growth Excluding Contributions from Paxlovid and Comirnaty (1) , Revenues Grew 12% Operationally Full-Year 2024 Reported (2) Diluted EPS of $1.41 and Adjusted (3) Diluted EPS of $3.11 Fourth-Quarter 2024 Revenues of $17.8 Billion, Reflecting 21% Year-over-Year Operational Growth Excluding Contributions from Paxlovid and Comirnaty (1) ,... Read More

BRAFTOVI in combination with cetuximab and mFOLFOX6 showed statistically significant and clinically meaningful improvement in progression-free survival and overall survival in patients with metastatic colorectal cancer with a BRAF V600E mutation BRAFTOVI combination regimen received accelerated approval for treatment-naïve patients in December 2024 Results to be shared with the U.S. FDA to support potential conversion to... Read More

More than 20 abstracts span Pfizer’s leading genitourinary cancer portfolio of approved standards of care and growing pipeline across prostate and bladder cancers Detailed overall survival (OS) results from the pivotal Phase 3 TALAPRO-2 trial of TALZENNA ® in combination with XTANDI ® in patients with metastatic castration-resistant prostate cancer (mCRPC) Updated analysis from the Phase 3 EV-302 trial highlights sustained... Read More

Clinically meaningful and statistically significant results from the Phase 3 BREAKWATER trial show objective response rate of 61% with Pfizer’s BRAFTOVI combination regimen compared to 40% with investigator’s choice of chemotherapy, representing a doubling of the odds of achieving an objective response BRAFTOVI combination regimen is the first and only targeted therapy approved by the U.S. FDA for treatment-naïve patients... Read More

Clinically meaningful and statistically significant results are the first pivotal Phase 3 data for sasanlimab, a subcutaneously administered PD-1 inhibitor If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population Treatment naïve high-risk NMIBC is an area of significant unmet need, where therapeutic options have largely... Read More

BRAFTOVI in combination with cetuximab and mFOLFOX6 is the first and only combination regimen with targeted therapy approved for use as early as first-line for patients with metastatic colorectal cancer with a BRAF V600E mutation Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the Phase 3 BREAKWATER trial NEW YORK / Dec 20, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) today... Read More

NEW YORK / Dec 19, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EST on Tuesday, February 4, 2025. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter and Full Year 2024 Performance Report, to be issued that morning. To view and... Read More

Full-Year 2025 Revenue Guidance (1) Range of $61.0 to $64.0 Billion Full-Year 2025 Adjusted (2) Diluted EPS Guidance Range of $2.80 to $3.00 Expect Full-Year 2025 Adjusted (2) Diluted EPS Operational (3) Growth of 10% to 18% from the Midpoint of 2024 Guidance After Adjusting for 2024 Non-Recurring Items (4) Achieved Goal of $4.0 Billion in Net Cost Savings Through 2024 and Anticipate an Additional $500 Million in Savings in... Read More

Board of Directors approves increase in quarterly cash dividend to $0.43 per share NEW YORK / Dec 12, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company’s common stock to $0.43 for the first-quarter 2025 dividend, payable March 7, 2025, to holders of the Common Stock of record at the close of business on January 24,... Read More

IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy NEW YORK / Dec 12, 2024 / Business Wire / Pfizer Inc. (NYSE:PFE) and Alliance Foundation Trials, LLC (AFT) today announced results from the Phase 3 PATINA trial demonstrating that the addition of IBRANCE ® (palbociclib) to current... Read More

NEW YORK / Dec 10, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 8:30 a.m. EST on Tuesday, December 17, 2024. The purpose of the call is to provide Pfizer’s full-year 2025 financial guidance. To view and listen to the webcast, visit our web site at www.pfizer.com/investors . Information on accessing and... Read More

NEW YORK / Dec 05, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) will highlight the latest advancements from its growing hematology and breast cancer portfolios at the American Society of Hematology (ASH) Annual Meeting & Exposition (December 7-10) and the San Antonio Breast Cancer Symposium (SABCS, December 10-13). Data from more than 100 company-sponsored, investigator-sponsored, and collaborative research abstracts,... Read More

Chris Boshoff to lead all Research and Development functions including Oncology Oncology Unit end-to-end structure to remain intact, reporting to Boshoff Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer NEW YORK / Nov 20, 2024 / Business Wire / Pfizer Inc . (NYSE: PFE) today announced that after a comprehensive internal and external selection... Read More

In the EU, HYMPAVZI is the first once-weekly subcutaneous treatment approved for eligible people living with severe hemophilia B and the first to be administered via a pre-filled pen or syringe for people living with severe hemophilia A or B HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without... Read More

NEW YORK / Nov 14, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Andrew Baum, Chief Strategy and Innovation Officer, Executive Vice President, and Dave Denton, Chief Financial Officer, Executive Vice President, at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 9:00 a.m. GMT. To view and listen to the... Read More

NEW YORK / Nov 04, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Aamir Malik, Chief U.S. Commercial Officer, Executive Vice President, at the UBS Global Healthcare Conference on Wednesday, November 13, 2024 at 12:30 p.m. PST. To view and listen to the webcast, visit our web site at www.pfizer.com/investors . Information on... Read More

Third-Quarter Performance Driven by Focused Commercial Execution and Robust Double-Digit Revenue Growth Across Product Portfolio Raises Full-Year 2024 Revenue Guidance (1) to a Range of $61.0 to $64.0 Billion and Raises Adjusted (2) Diluted EPS Guidance to a Range of $2.75 to $2.95 Third-Quarter 2024 Revenues of $17.7 Billion, Representing 32% Year-over-Year Operational Growth Excluding Contributions from Paxlovid and... Read More

Millions of newly eligible U.S. adults aged 50 to 64 now recommended to receive vaccination against invasive pneumococcal disease (IPD) and pneumococcal pneumonia 1 NEW YORK / Oct 23, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practice (ACIP) voted to expand its recommendation for the use of certain... Read More

First and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 Approval based on data from pivotal Phase 3 trial in adults at increased risk of lower respiratory tract disease caused by RSV NEW YORK / Oct 22, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO ® (Respiratory Syncytial Virus Vaccine), the company’s... Read More

NEW YORK / Oct 15, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced the election of Mortimer (“Tim”) J. Buckley to its Board of Directors, effective immediately, following a lengthy and comprehensive search that began in May 2024. Mr. Buckley, age 55, was also appointed to and will join the Governance and Sustainability Committee and the Audit Committee of Pfizer’s Board. Following the appointment of Mr.... Read More

HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis and on-demand treatment in eligible patients with hemophilia A or B without inhibitors In the U.S., HYMPAVZI is the first once-weekly subcutaneous prophylactic treatment for eligible people living with hemophilia B, and the first to be administered via a pre-filled pen or syringe for eligible people... Read More

First and only PARP inhibitor plus ARPI combination to demonstrate statistically significant overall survival (OS) benefit in patients with metastatic castration-resistant prostate cancer (mCRPC) Results to be shared with global health authorities to potentially update the TALZENNA label NEW YORK / Oct 10, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified... Read More

Board of Directors approves quarterly cash dividend of $0.42 per share NEW YORK / Oct 09, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 fourth-quarter 2024 dividend on the company’s common stock, payable December 2, 2024, to holders of the Common Stock of record at the close of business on November 8, 2024. The fourth-quarter 2024 cash dividend will be the 344th... Read More

Presentations highlight momentum of Pfizer’s portfolio of infectious disease prevention and treatment options NEW YORK / Oct 08, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) will present data across its infectious disease portfolio at the upcoming IDWeek 2024 congress, held in Los Angeles from October 16-19, 2024. Data in 49 abstracts from company- and collaborator-led studies, will highlight the advances Pfizer is making... Read More

NEW YORK / Sep 25, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide. Pfizer's decision is based on the totality of clinical data that now... Read More

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted COVID-19 vaccine generates a substantially improved response against multiple circulating Omicron JN.1 sublineages as did the Omicron JN.1-adapted COVID-19 vaccine authorized by the European Commission in July 2024 Doses will be... Read More

NEW YORK / Sep 17, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, October 29, 2024. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2024 Performance Report, to be issued that morning. To view and listen to the... Read More

Study met primary endpoint of change from baseline in body weight for ponsegromab compared to placebo across all ponsegromab doses tested, reaching 5.6% mean increase at the highest dose evaluated at 12 weeks; ponsegromab was generally considered safe and well-tolerated at all dose levels i At the highest dose evaluated, improvements were seen from baseline in appetite and cachexia symptoms, physical activity, and muscle... Read More

BRAFTOVI + MEKTOVI continued to show substantial antitumor activity after a minimum follow up of approximately three years, corresponding to the longest duration of response and progression-free survival in treatment-naïve patients compared to historical outcomes Results support BRAFTOVI + MEKTOVI as a standard of care option for this population NEW YORK / Sep 14, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) today... Read More

More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies Two late-breaking presentations include longer-term results from BRAFTOVI ® + MEKTOVI ® PHAROS study in BRAF V600E-mutant metastatic NSCLC and new Phase 2 ponsegromab data in cancer cachexia Encouraging early results for PD-L1 vedotin ADC, disitamab vedotin and the novel combination of CDK4 +... Read More

VLA15-221 Phase 2 study: strong immune response shown one month after a second booster dose (month 31) in pediatric and adult populations Significant anamnestic antibody response observed across all six serotypes, consistent with previous results Favorable safety profile of VLA15 observed in all age groups and for all vaccinations Saint-Herblain (France) and New York, NY, September 3, 2024 – Valneva SE (Nasdaq: VALN;... Read More

NEW YORK / Aug 28, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the Morgan Stanley 22 nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 8:30 a.m. EDT. To view and listen to the webcast, visit our web site at www.pfizer.com/investors.... Read More

PfizerForAll makes managing everyday health quicker and more convenient for millions of Americans Platform is designed for patients with migraine, COVID-19 or flu, and adults seeking vaccines for preventable diseases, including COVID-19, flu, RSV and pneumococcal pneumonia End-to-end offering gives people an easier way to connect with a qualified healthcare professional the same day, find and book vaccines, receive tests and... Read More

The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older The KP.2 adaptation is based on FDA guidance, which stated that KP.2 is the preferred strain for COVID-19 vaccines for the US 2024-2025 fall and winter season, if feasible Shipping will begin immediately to ensure robust supply and rapid access of this season’s... Read More

In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives The trial did not meet one of its primary immunogenicity objectives of non-inferiority against the influenza B strain despite obtaining higher influenza A responses and comparable COVID-19 responses versus the comparator vaccines The companies are evaluating adjustments... Read More

First assessment from an RSV vaccine study in immunocompromised adults show ABRYSVO was well-tolerated and generated strong neutralizing responses after a single dose in adults ≥ 18 years of age These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV NEW YORK / Aug 12, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced... Read More

Largest head-to-head randomized clinical trial between DTG/3TC and BIC /FTC/TAF, conducted by SEIMC-GeSIDA Foundation (FSG) showed DTG/3TC demonstrated non-inferior efficacy compared to BIC /FTC/TAF as a switch regimen for virologically-suppressed adults living with HIV over 48 weeks of therapy. DTG/3TC-treated individuals had significantly less weight gain compared to those randomized to BIC /FTC/TAF. In 2022, the Canadian... Read More

Second-Quarter Performance Driven by Focused Commercial Execution Raises Full-Year 2024 Revenue Guidance (1) to a Range of $59.5 to $62.5 Billion and Raises Adjusted (2) Diluted EPS Guidance to a Range of $2.45 to $2.65 Launched Manufacturing Optimization Program with Anticipated Cost Savings of Approximately $1.5 Billion by the End of 2027 Second-Quarter 2024 Revenues of $13.3 Billion Revenues Grew 3% Operationally... Read More

A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9) after up to four years of follow-up, providing sustained bleed protection and potentially avoiding years of treatment burden with prophylaxis for many patients. NEW YORK / Jul 25, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced that the European... Read More

Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis NEW YORK / Jul 24, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 AFFINE study ( NCT04370054 ) evaluating giroctocogene fitelparvovec, an investigational gene therapy for the treatment of adults with moderately severe to severe hemophilia A. The AFFINE... Read More

Clinical evaluation of several modified release once-daily formulations of danuglipron resulted in encouraging pharmacokinetic data for several candidates with one showing the most favorable profile The company plans to conduct dose optimization studies with a focus on the preferred formulation to inform the registration enabling studies NEW YORK / Jul 11, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced that... Read More

NEW YORK / Jul 09, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced that the company is launching the process to identify a successor for Dr. Mikael Dolsten, Pfizer’s Chief Scientific Officer and President, Pfizer Research & Development, who will depart the company after a more than 15-year stellar career. This process is expected to last several months, probably through early next year. Pfizer will initiate an... Read More

NEW YORK / Jul 01, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced the election of Cyrus Taraporevala to its Board of Directors, effective immediately. Mr. Taraporevala, age 57, was also appointed to and will join the Audit Committee and Compensation Committee of Pfizer’s Board. Mr. Taraporevala served as President and Chief Executive Officer at State Street Global Advisors from 2017 until his retirement in... Read More

The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older Recommendation is based on pre-clinical and epidemiological data showing that the JN.1-adapted monovalent COVID-19 vaccine generates an improved immune response against multiple JN.1 sublineages Doses will be ready to ship to applicable EU member states immediately upon authorization... Read More

Board of Directors approves quarterly cash dividend of $0.42 per share NEW YORK / Jun 26, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 third-quarter 2024 dividend on the company’s common stock, payable September 3, 2024, to holders of the Common Stock of record at the close of business on July 26, 2024. The third-quarter 2024 cash dividend will be the 343rd... Read More

NEW YORK / Jun 18, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EDT on Tuesday, July 30, 2024. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2024 Performance Report, to be issued that morning. To view and listen to the... Read More

Patients in MagnetisMM-3 demonstrated a median overall survival (OS) of 24.6 months, with median progression-free survival (PFS) of 17.2 months NEW YORK / Jun 14, 2024 / Business Wire / Pfizer Inc . (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ (elranatamab-bcmm) in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM). The study... Read More

NEW YORK / Jun 12, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy, fordadistrogene movaparvovec, in ambulatory patients with Duchenne muscular dystrophy (DMD) did not meet its primary endpoint of improvement in motor function among boys 4 to 7 years of age... Read More

NEW YORK / Jun 03, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 45 th Annual Global Healthcare Conference on Monday, June 10, 2024 at 11:20 a.m. Eastern Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com/investors . Information on accessing... Read More

Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone, resulting in median overall survival of 13.8 months versus 8.5 months Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen NEW YORK / Jun 01, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) today... Read More

An unprecedented 60% of patients remain alive without disease progression after five years Updated results show continued 81% reduction in risk of progression or death and 94% reduction in progression of brain metastases compared to XALKORI ® NEW YORK / May 31, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 3 CROWN trial evaluating LORBRENA ® (lorlatinib, a... Read More

16 abstracts feature new data and post-hoc analyses of pivotal trials across several types of hard-to-treat cancers TOKYO , May 13, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") will share new research from across its innovative portfolio of approved and investigational cancer therapies during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May... Read More

NEW YORK / May 06, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced that Andrew Baum, M.D., will join the company as Chief Strategy and Innovation Officer, Executive Vice President. Dr. Baum will be a member of Pfizer’s Executive Leadership Team reporting to Chairman and Chief Executive Officer, Dr. Albert Bourla. He joins Pfizer from Citi, where he served as Head of Global Healthcare, Managing Director Equity... Read More

Solid First-Quarter Results Reflect Continued Growth of Key Products and Progress in Executing 2024 Priorities First-Quarter 2024 Revenues of $14.9 Billion Expected Decline in Comirnaty (1) and Paxlovid Revenues Drove a Year-Over-Year Operational Decrease in Revenues of 19% Excluding Contributions from Comirnaty (1) and Paxlovid, Revenues Grew 11% Operationally First-Quarter 2024 Reported (2) Diluted EPS of $0.55 and... Read More

TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer Conversion to full approval from accelerated approval is based on positive results from global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapy NEW YORK & COPENHAGEN, Denmark / Apr 29, 2024 / Business Wire / Pfizer Inc.... Read More

More than 50 abstracts, including 11 oral presentations, span Pfizer’s robust portfolio of approved and pipeline therapies across its key tumor areas and core scientific modalities New five-year progression-free survival data for LORBRENA ® (lorlatinib) in first-line ALK-positive advanced lung cancer Results from ECHELON-3, third Phase 3 study to demonstrate overall survival benefit for ADCETRIS ® (brentuximab vedotin) in a... Read More

A one-time dose of BEQVEZ has reduced bleeds post-treatment compared to standard of care with a median of zero bleeds (range 0 to 19) after up to three years of follow-up, providing sustained bleed protection and potentially avoiding years of treatment burden with prophylaxis for many patients NEW YORK / Apr 26, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA)... Read More

Board of Directors approves quarterly cash dividend of $0.42 per share NEW YORK / Apr 24, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 second-quarter 2024 dividend on the company’s common stock, payable June 14, 2024, to holders of the Common Stock of record at the close of business on May 10, 2024. The second-quarter 2024 cash dividend will be the 342nd... Read More

EMBLAVEO ® is the first β-lactam/β-lactamase inhibitor antibiotic combination approved in the European Union for treating serious infections in adult patients caused by multidrug-resistant Gram-negative bacteria, including metallo-β-lactamase-producing bacteria EMBLAVEO ® was reviewed under European Medicines Agency accelerated assessment procedure, used when a pharmaceutical product is of major interest for public health... Read More

NEW YORK / Apr 11, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual-only 2024 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 25, 2024. Pfizer has designed the virtual Annual Meeting to ensure that its shareholders who attend the virtual-only Annual Meeting will be afforded comparable rights and opportunities to... Read More

ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk. The vaccine was well-tolerated and demonstrated an immune response non-inferior to adults aged 60 years and older Pfizer intends to submit these findings to regulatory agencies to seek approval of ABRYSVO in adults 18 to 59 years of age NEW YORK / Apr 09, 2024 / Business Wire / Pfizer Inc. (NYSE:... Read More

NEW YORK / Mar 20, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Wednesday, May 1, 2024. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2024 Performance Report, to be issued that morning. To view and listen to the webcast... Read More

PREVENAR 20 ® (20-valent Pneumococcal Conjugate Vaccine) offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the EU and globally 1,2,3,4,5,6,7,8 NEW YORK / Mar 13, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced that the European Commission... Read More

ECHELON-3 trial of ADCETRIS in combination with lenalidomide and rituximab showed significant improvement in primary endpoint of overall survival and in secondary endpoints of progression free survival and overall response rate versus lenalidomide and rituximab plus placebo, regardless of CD30 expression Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS NEW YORK / Mar 12,... Read More

NEW YORK / Mar 05, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) invites investors and the general public listen to a webcast of a discussion with Mikael Dolsten, Chief Scientific Officer & President, Pfizer Research and Development, at the Leerink Partners Global Biopharma Conference 2024 on Tuesday, March 12, 2024 at 8:00 a.m. Eastern Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com/investors... Read More

Company unveils new innovative Oncology organization, strategic vision and approach, following the Seagen acquisition in late 2023 Robust portfolio and R&D engine with 8+ potential blockbuster medicines by 2030 Multiple near- and mid-term catalysts expected to help drive long-term sustainable growth NEW YORK / Feb 29, 2024 / Business Wire / At a meeting with the investment community today, Pfizer Inc. (NYSE: PFE) outlined... Read More

ABRYSVO, a bivalent vaccine, maintained consistently high protective efficacy for both RSV A and RSV B disease through two seasons after a single dose. ABRYSVO efficacy was 77.8% against RSV lower respiratory tract disease with three or more symptoms in a second full RSV season in adults 60 years of age or older. NEW YORK / Feb 29, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced top-line ABRYSVO ® vaccine... Read More

NEW YORK / Feb 26, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the TD Cowen 44 th Annual Health Care Conference on Monday, March 4, 2024 at 11:10 a.m. Eastern Standard Time. To listen to the webcast, visit our web site at www.pfizer.com/investors . Information on... Read More

VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU NEW YORK / Feb 19, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for VELSIPITY ® (etrasimod) in the European Union to treat patients 16 years of age and older with moderately to severely active ulcerative... Read More

NEW YORK / Feb 15, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) invites investors and the general public to access a live video webcast of its Oncology Innovation Day on Thursday, February 29, 2024, from 1:00 p.m. EST to 5:30 p.m. EST, with an approximately 20-minute break at the midpoint. During the event, Pfizer Oncology leadership will provide details on the new combined Pfizer Oncology Division, including its strategic... Read More

The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes” aims to enhance awareness of and access to cancer screening, clinical trials and support in medically underrepresented communities across the United States ATLANTA & NEW YORK / Feb 05, 2024 / Business Wire / The American Cancer Society (ACS) and Pfizer Inc. (NYE: PFE) today announced the launch of “Change the Odds™: Uniting to Improve Cancer Outcomes,” a... Read More

2023 Sets Stage for Future Growth Potential: Completed Seagen Acquisition, Creating World-Class Oncology Organization; Launched Significant Number of New Products and Indications; and Realigned Commercial Organization to Improve Focus, Speed and Execution Full-Year 2023 Revenues of $58.5 Billion Expected Decline in Comirnaty (1) and Paxlovid Revenues Drove 41% Operational Decrease in Year-Over-Year Revenues Excluding... Read More

Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival If approved, PADCEV with KEYTRUDA would be the first combination in the EU to offer an alternative to platinum-containing chemotherapy, the current standard of care in first-line locally... Read More

NEW YORK / Jan 10, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation of Ontario, Canada to purchase up to 4 million shares of Pfizer common stock at a price of $27.35 per share in cash. TRC Capital Investment’s offer price of $27.35 per share is approximately 4.4 percent lower than the $28.61 closing share price... Read More

Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy NEW YORK & COPENHAGEN, Denmark / Jan 09, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) seeking to convert the accelerated approval of... Read More

TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the Europe Union NEW YORK / Jan 08, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® (enzalutamide), for the treatment of adult patients... Read More

NEW YORK / Jan 02, 2024 / Business Wire / Pfizer Inc . (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 3:00 p.m. PST. To listen to the webcast, visit our web site at www.pfizer.com/investors . Information on accessing and registering for the... Read More

NEW YORK / Dec 19, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 30, 2024. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter and Full Year 2023 Performance Report, to be issued that morning. To view and listen... Read More

Board of Directors approves increase in quarterly cash dividend to $0.42 per share NEW YORK / Dec 14, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company’s common stock to $0.42 for the first-quarter 2024 dividend, payable March 1, 2024, to holders of the Common Stock of record at the close of business on January 26,... Read More

Further establishes Pfizer as a leading oncology company poised to accelerate the next generation of breakthrough treatments for people with cancer To address U.S. Federal Trade Commission concerns, Pfizer has chosen to irrevocably donate the rights of royalties from sales of Bavencio ® (avelumab) in the U.S. to the American Association for Cancer Research (AACR) NEW YORK / Dec 14, 2023 / Business Wire / Pfizer Inc. (NYSE:... Read More

Full-Year 2024 Revenue Guidance (1) Range of $58.5 to $61.5 Billion Includes Expected Contribution from Seagen Acquisition Anticipates Approximately $8 Billion in Revenues for Comirnaty (2) and Paxlovid Seagen Expected to Contribute Approximately $3.1 Billion of Revenues Expects Full-Year 2024 Operational (3) Revenue Growth of 8%-10% Including Seagen Contribution and Excluding Comirnaty (2) and Paxlovid Revenues, and 3%-5%... Read More

Expects to close Seagen acquisition on December 14, 2023 Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution Pfizer to host analyst and investor call at 8:30 am EST on Wednesday, December 13, 2023, to discuss the Seagen acquisition, new commercial organization, and provide full-year 2024 financial guidance NEW YORK / Dec 12, 2023 / Business Wire / Pfizer Inc. (NYSE:... Read More

Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting If approved in the U.S. and EU, marstacimab could become the first once-weekly subcutaneous treatment for people living with hemophilia B and the first treatment administered as a flat dose for people living with hemophilia A or B NEW YORK / Dec 11, 2023 / Business... Read More

Marstacimab reduced annualized bleeding rate by 35% and 92% compared to routine prophylaxis and on-demand treatment in patients with hemophilia A and B without inhibitors, respectively Consistent reduction in bleeding rates observed after an additional 16 months of follow-up in the trial’s long-term extension observational study NEW YORK / Dec 09, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) today presented results from... Read More

Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial ELREXFIO is an off-the-shelf (ready-to-use), fixed-dose, subcutaneous BCMA-directed bispecific antibody immunotherapy with reduced dosing after 24 weeks for responding patients NEW YORK / Dec 08, 2023 / Business Wire / Pfizer Inc. (NYSE:PFE) today announced the European... Read More

Danuglipron demonstrated mean placebo-adjusted weight reductions ranging from -8% to -13% at 32 weeks and -5% to -9.5% at 26 weeks While most common adverse events were mild and gastrointestinal in nature consistent with the mechanism, high rates were observed; no new safety signals were observed High discontinuation rates, greater than 50%, were seen across all doses compared to approximately 40% with placebo Ongoing... Read More

NEW YORK / Nov 21, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023 at 10:50 a.m. EST. To view and listen to the webcast, visit our web site at www.pfizer.com/investors . Information on accessing and... Read More

XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy* in nonmetastatic castration-sensitive prostate cancer TOKYO and NEW YORK , Nov. 16, 2023 /PRNewswire/ -- Astellas Pharma Inc. ( TSE: 4503, President and CEO: Naoki Okamura , "Astellas") and Pfizer Inc. (NYSE: PFE) today announced that the companies received an approval by the U.S. Food and Drug... Read More

39 presentations span ten medicines, including six in Pfizer’s pipeline, being studied for the treatment of hemophilia, sickle cell disease, and blood cancer Presentations include primary analysis from pivotal Phase 3 BASIS trial of marstacimab in hemophilia A&B, initial Phase 2/3 results from GBT601 study in sickle cell disease, and data from the broad MagnetisMM multiple myeloma program supporting the favorable profile of... Read More

NEW YORK / Nov 02, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Aamir Malik, Chief Business Innovation Officer, Executive Vice President, at the Truist Securities BioPharma Symposium on Thursday, November 9, 2023 at 12:35 p.m. EST. To view and listen to the webcast, visit our web site at www.pfizer.com/investors . Information on... Read More

Third-Quarter 2023 Revenues of $13.2 Billion Expected Decline in Paxlovid and Comirnaty (1) Revenues Drove 41% Operational Decrease in Third-Quarter 2023 Revenues Revenues for Pfizer’s Non-COVID Products Grew 10% Operationally Third-Quarter 2023 Reported (2) Diluted Loss Per Share (LPS) of $(0.42) and Adjusted (3) Diluted LPS of $(0.17), Significantly Impacted by $5.6 Billion of Non-Cash Inventory Write-Offs and Other... Read More

Lead formulations evaluated in the Phase 1/2 study demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains Safety profile of the mRNA-based combination vaccine candidates consistent with the companies’ COVID-19 vaccine The companies plan to start a pivotal Phase 3 trial in the coming months NEW YORK & MAINZ, GERMANY / Oct 26, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) and BioNTech SE... Read More

PENBRAYA™ provides the broadest serogroup coverage (meningococcal groups A, B, C, W and Y) of any meningococcal vaccine available in the U.S. and has the potential to help simplify complex vaccination schedule in the U.S. The FDA’s decision is based on data from Phase 2 and Phase 3 trials, which demonstrated that PENBRAYA has robust immunogenicity non-inferior to Trumenba ® + Menveo ® for all serogroups and was... Read More

SHANGHAI , Oct. 15, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) has received approval from the U.S. Food and Drug Administration (FDA) for VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative colitis (UC). Importantly, VELSIPITY™'s label does... Read More

Data include three late-breaking abstracts, underscoring Astellas' efforts to potentially redefine expectations for patients across its oncology portfolio TOKYO , Oct. 15, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") will share new research results during the European Society for Medical Oncology (ESMO) Congress 2023 from October 20-24 , showcasing the company's focus... Read More

Removes a Significant Uncertainty by Providing Pathway to U.S. Commercialization of Paxlovid on January 1, 2024 with Amended Supply Agreement In a Non-Cash Transaction, U.S. Government to Return Estimated 7.9 Million EUA-Labeled Paxlovid Treatment Courses at end of 2023 and Receive Credit for Future NDA-labeled Treatment Courses from Pfizer Credit will Support a Patient Assistance Program to Provide Paxlovid Free of Charge... Read More

Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials NEW YORK / Oct 13, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative... Read More

BRAFTOVI + MEKTOVI now gives adult patients with BRAF V600E-mutant metastatic non-small cell lung cancer a new personalized treatment option NEW YORK / Oct 12, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI ® (encorafenib) + MEKTOVI ® (binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with... Read More

Presentations showcase diversity and momentum of Pfizer’s growing portfolio of vaccines and anti-infectives NEW YORK / Oct 05, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) will present data across its infectious disease portfolio at the upcoming IDWeek 2023 held in Boston from October 11-15, 2023. Data from 45 abstracts will highlight the advances Pfizer is making in helping prevent and treat certain infectious diseases,... Read More

Board of Directors approves quarterly cash dividend of $0.41 per share NEW YORK / Oct 04, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.41 fourth-quarter 2023 dividend on the company’s common stock, payable December 4, 2023, to holders of the Common Stock of record at the close of business on November 10, 2023. The fourth-quarter 2023 cash dividend will be the 340th... Read More

ABRYSVO recommended by CDC Advisory Committee for pregnant persons 32 through 36 weeks gestation to help protect infants from respiratory syncytial virus (RSV) from birth through first six months of life RSV maternal immunization recommendation adds to Pfizer’s respiratory vaccines offerings already available to help protect against RSV in older adults, COVID-19, and pneumococcal pneumonia in adults NEW YORK / Sep 22, 2023 /... Read More

NEW YORK / Sep 19, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023 at 3:30 p.m. EDT. To view and listen to the webcast, visit our web site at www.pfizer.com/investors . Information on accessing and... Read More

NEW YORK / Sep 19, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for LITFULO™ (ritlecitinib) to treat adults and adolescents 12 years of age and older with severe alopecia areata. LITFULO, a once-daily oral capsule, is the first medicine authorized by the EC to treat individuals as young as 12 years of age with severe alopecia areata.... Read More

NEW YORK / Sep 18, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 31, 2023. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2023 Performance Report, to be issued that morning. To view and listen to the webcast... Read More

Application based on results from Phase 3 EMBARK trial, which showed XTANDI plus leuprolide reduced risk of metastasis or death by 58% TOKYO , Sept. 12, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced that the European Medicines Agency (EMA) has validated its Type II variation for XTANDI ® (enzalutamide) for the treatment of patients with non-metastatic... Read More

NEW YORK / Sep 12, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the J.P. Morgan 14 th Annual U.S. All Stars Conference on Monday, September 18, 2023 at 11:00 a.m. BST. To view and listen to the webcast, visit our web site at www.pfizer.com/investors . Information... Read More

This season’s vaccine is tailored to the SARS-CoV-2 XBB.1.5 sublineage and indicated as a single dose for most individuals 5 years of age and older Pre-clinical data show that the updated COVID-19 vaccine generates improved neutralizing antibody responses against multiple circulating Omicron-related sublineages including XBB.1.5, BA.2.86 (Pirola), and EG.5.1 (Eris), which currently accounts for the largest portion of U.S.... Read More

NEW YORK / Sep 05, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Angela Hwang, Chief Commercial Officer, President, Global Biopharmaceuticals Business, and Suneet Varma, Global Oncology and U.S. President, at the Morgan Stanley 21 st Annual Global Healthcare Conference on Monday, September 11, 2023 at 12:15 p.m. EDT. To view and... Read More

NEW YORK / Aug 30, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to two upcoming webcasts of Pfizer discussions at healthcare conferences: Annaliesa Anderson, SVP & Head, Vaccines Research & Development; and Rodrigo Puga, U.S. Commercial and Global Business Lead for Internal Medicine, at the Wells Fargo 2023 Healthcare Conference on Wednesday, September 6, 2023 at... Read More

The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older Recommendation is based on pre-clinical data showing that the Omicron XBB.1.5-adapted monovalent COVID-19 vaccine generates an improved response against multiple XBB-related sublineages, including XBB.1.5, XBB.1.16, XBB.2.3, and EG.5.1 (Eris), which continue to dominate... Read More

ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for both older adults and for immunization of pregnant individuals to help protect their infants immediately from birth through six months of age NEW YORK / Aug 24, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for ABRYSVO ™ , the company’s bivalent respiratory... Read More

SHANGHAI , Aug. 23, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its interim results for the first half of 2023, along with a corporate update. "We are pleased to have achieved a number of critical milestones during the first half of 2023,... Read More

If approved, XTANDI would become the first and only novel hormone therapy approved in this earlier type of prostate cancer NEW YORK and TOKYO , Aug. 23, 2023 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the companies' supplemental New Drug... Read More

First and only U.S. approval of a maternal vaccine to help protect infants at birth through six months of life from lower respiratory tract disease (LRTD) and severe LRTD due to RSV FDA’s decision is based on data from the pivotal Phase 3 clinical trial in more than 7,000 pregnant individuals, and including their infants a total greater than 14,000 trial participants NEW YORK / Aug 21, 2023 / Business Wire / Pfizer Inc.... Read More

The approval of ELREXFIO (elranatamab-bcmm) is based on clinically meaningful response rates and duration of response from Phase 2 MagnetisMM-3 study ELREXFIO is the first off-the-shelf (ready-to-use) fixed-dose subcutaneous BCMA-directed agent in the U.S. with the option for every-other-week long-term dosing after 24 weeks of weekly treatment Pfizer continues to advance the MagnetisMM clinical program to expand ELREXFIO... Read More

Second-Quarter 2023 Revenues of $12.7 Billion Expected Decline in Paxlovid and Comirnaty (1) Revenues Drove 53% Operational Decrease in Second-Quarter 2023 Revenues Second-Quarter 2023 Revenues from Comirnaty (1) and Paxlovid of $1.6 Billion Excluding Contributions from Comirnaty (1) and Paxlovid, Revenues Grew 5% Operationally Second-Quarter 2023 Reported Diluted EPS (2) of $0.41, a Year-Over-Year Decline of 77%, and... Read More

NEW YORK / Jul 27, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced changes to its executive leadership team to further advance its aspirations to discover and develop new medicines and vaccines, with an emphasis on oncology. Effective today, Chris Boshoff, M.D., PhD, will join Pfizer’s Executive Leadership Team as Chief Oncology Research and Development Officer and Executive Vice President reporting to... Read More

Pfizer confirms all its colleagues are safe following a tornado that damaged predominantly the warehouse portion of its manufacturing facility in Rocky Mount, North Carolina on Wednesday Pfizer and the Pfizer Foundation pledge financial support to help local communities affected by the devastating natural disaster Pfizer working with state, local and federal officials, including U.S. Food and Drug Administration Commissioner... Read More

Results from an ongoing Phase 2 study in pregnant individuals showed the investigational vaccine, GBS6, was generally well-tolerated and generated robust maternal antibody responses that were efficiently transferred to infants The safety profile between the vaccine and placebo groups was similar in both the mothers and infants GBS6 maternal vaccination may offer meaningful protection against invasive GBS disease in newborns... Read More

Flagship Pioneering and Pfizer to invest a total of $100M upfront to explore opportunities to develop 10 single-asset programs within Pfizer's core strategic areas of interest and addressing unmet needs, including in broad patient populations Pioneering Medicines, an initiative of Flagship Pioneering, working in collaboration with Pfizer's research and development leadership, will lead the exploration process to drive rapid... Read More

DUBLIN, Ireland and BOSTON, July 06, 2023 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced a clinical trial collaboration and supply agreement with Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE). This agreement covers the execution of a Phase 1b/2 clinical trial to evaluate the novel combination of... Read More

New, longer-acting treatment offers option to reduce the frequency of injections for children with growth hormone deficiency from daily to once-weekly NEW YORK & MIAMI / Jun 28, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog indicated for... Read More

Regulatory application also under review with EMA Submissions based on positive Phase 3 data from BENEGENE-2 trial NEW YORK / Jun 27, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for fidanacogene elaparvovec for the treatment of adults with hemophilia B. In parallel, the European marketing... Read More

Pfizer is continuing to advance the first full agonist oral GLP-1-RA candidate danuglipron toward late-state development Danuglipron is the largest oral, small molecule GLP-1-RA clinical development program underway with over 1,400 participants enrolled for the treatment of obesity and T2DM Ongoing danuglipron Phase 2b study in obesity is fully enrolled Second GLP-1-RA candidate lotiglipron to be discontinued NEW YORK / Jun... Read More

LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12 NEW YORK / Jun 23, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved LITFULO ™ (ritlecitinib), a once-daily oral treatment, for individuals 12 years of age and older with severe alopecia areata. The approved recommended dose for LITFULO is 50 mg. It... Read More

Board of Directors approves quarterly cash dividend of $0.41 per share NEW YORK / Jun 22, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.41 third-quarter 2023 dividend on the company’s common stock, payable September 5, 2023, to holders of the Common Stock of record at the close of business on July 28, 2023. The third-quarter 2023 cash dividend will be the 339th... Read More

TALZENNA is first and only PARP inhibitor approved for use with an existing standard of care (XTANDI) for adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration resistant prostate cancer (mCRPC) NEW YORK / Jun 20, 2023 / Business Wire / Pfizer (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved TALZENNA (talazoparib), an oral poly ADP-ribose... Read More

NEW YORK / Jun 20, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, August 1, 2023. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2023 Performance Report, to be issued that morning. To view and listen to the webcast... Read More

NEW YORK / Jun 06, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with William Pao, Chief Development Officer, Executive Vice President, at the Goldman Sachs 44 th Annual Global Healthcare Conference on Tuesday, June 13, 2023 at 8:00 a.m. Pacific Daylight Time. To view and listen to the webcast, visit our web site at... Read More

Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone NEW YORK / Jun 01, 2023 / Business Wire / Pfizer Inc . (NYSE: PFE) today announced positive results from the Phase 3 program comprising the REVISIT ( NCT03329092 ) and ASSEMBLE ( NCT03580044 ) studies evaluating the efficacy,... Read More

FDA’s decision is based on the data from the pivotal Phase 3 clinical trial in approximately 37,000 participants Each year in the U.S., it is estimated that between 60,000 and 160,000 older adults are hospitalized and between 6,000 and 10,000 die due to RSV infection 1 ABRYSVO’s approval will help offer older adults protection in the anticipated RSV season this fall NEW YORK / May 31, 2023 / Business Wire / Pfizer Inc.... Read More

Study demonstrates statistically significant and clinically relevant reduction in annualized bleeding rate compared to prophylaxis and on-demand intravenous regimens Marstacimab, if approved, has the potential to become the first once-weekly subcutaneous treatment for people living with hemophilia B and the first treatment administered as a flat dose for people living with hemophilia A or B A novel, investigational... Read More

Data at meeting illustrate company's progress in addressing unmet needs in a broad range of hard-to-treat solid tumors and hematologic malignancies TOKYO , May 25, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") will share new research from across its expanding portfolio of approved and investigational cancer therapies during the 2023 American Society of Clinical Oncology... Read More

Data spans 15+ therapies across 10+ types of cancer, including six early pipeline medicines New data will be presented for three potential therapies with regulatory decisions anticipated this year in certain types of multiple myeloma, prostate cancer, and non-small cell lung cancer NEW YORK / May 25, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) will present data across its Oncology portfolio and growing pipeline, covering... Read More

PAXLOVID is the first FDA-approved oral treatment for COVID-19; has been authorized for emergency use since December 2021 Approval is based on the totality of scientific evidence submitted, including efficacy data from the Phase 2/3 EPIC-HR study showing an 86% reduction in risk of COVID-19-related hospitalization or death from any cause in patients who took PAXLOVID within five days of symptom onset PAXLOVID remains... Read More

The positive vote is based on compelling scientific evidence presented, including Phase 3 efficacy and safety data in pregnant individuals and their infants FDA decision expected in August 2023 If authorized, the vaccine candidate would help protect infants at first breath through six months of life against RSV disease and its potential complications NEW YORK / May 18, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) announced... Read More

NEW YORK / May 16, 2023 / Business Wire / Pfizer Inc. (NYSE:PFE) (“Pfizer”) today announced the pricing of a debt offering consisting of eight tranches of notes (collectively, the “Notes”): $3,000,000,000 aggregate principal amount of 4.650% Notes due 2025 $3,000,000,000 aggregate principal amount of 4.450% Notes due 2026 $4,000,000,000 aggregate principal amount of 4.450% Notes due 2028 $3,000,000,000 aggregate principal... Read More

NEW YORK / May 15, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) (“Pfizer”) today announced that its wholly owned subsidiary, Pfizer Investment Enterprises Pte. Ltd. (the “Issuer”), has commenced a multi-series offering of senior unsecured notes (the “Notes”). The maturity dates of the Notes are expected to range from two to 40 years. The Notes will be fully and unconditionally guaranteed on a senior unsecured basis by... Read More

First-Quarter 2023 Revenues of $18.3 Billion Expected Decline in Comirnaty (1) Revenue Drove 26% Operational Decrease in First-Quarter 2023 Revenues First-Quarter 2023 Revenues from Comirnaty (1) and Paxlovid of $7.1 Billion Excluding Contributions from Comirnaty (1) and Paxlovid, Revenues Grew 5% Operationally First-Quarter 2023 Reported Diluted EPS (2) of $0.97, a Year-Over-Year Decline of 29%, and Adjusted Diluted EPS (3)... Read More

Data from Phase 3 EMBARK trial to be presented as a plenary session during the 2023 American Urological Association Annual Meeting Results show the potential for XTANDI to add to the standard of care in prostate cancer, if approved TOKYO and NEW YORK , April 29, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President... Read More

PREVNAR 20 offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine, helping to protect against all 20 serotypes contained in the vaccine PREVNAR 20 builds on PREVNAR 13 ® and includes seven additional serotypes shown to be associated with antibiotic resistance, heightened disease severity, invasive potential, and prevalence in pediatric pneumococcal cases. 1 The vaccine further advances Pfizer’s... Read More

Board of Directors approves quarterly cash dividend of $0.41 per share NEW YORK / Apr 26, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.41 second-quarter 2023 dividend on the company’s common stock, payable June 9, 2023, to holders of the Common Stock of record at the close of business on May 12, 2023. The second-quarter 2023 cash dividend will be the 338th... Read More

NEW YORK / Apr 13, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual-only 2023 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 27, 2023. Pfizer has designed the virtual Annual Meeting to ensure that its shareholders who attend the virtual-only Annual Meeting will be afforded comparable rights and opportunities to... Read More

sNDAs are supported by results from the PHAROS trial, evaluating the combination in BRAF V600E-mutant metastatic non-small cell lung cancer NEW YORK / Apr 04, 2023 / Business Wire / Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental New Drug Applications (sNDAs) for BRAFTOVI ® (encorafenib) + MEKTOVI ® (binimetinib) for patients with metastatic... Read More

NEW YORK / March 29, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 2, 2023. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2023 Performance Report, to be issued that morning. To view and listen to the webcast... Read More

Pfizer and Astellas announce positive topline results from Phase 3 EMBARK trial NEW YORK and TOKYO , March 16, 2023 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced positive topline results from the Phase 3 EMBARK trial evaluating XTANDI ® (enzalutamide) in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also... Read More

NEW YORK / Mar 16, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted 16 to 1 that available data support the safety and effectiveness of PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets) for the treatment of mild-to-moderate COVID-19 in adult patients who are at high risk for progression to severe... Read More

XTANDI ® (enzalutamide) plus androgen deprivation therapy (ADT) significantly delays time to PSA progression compared to placebo plus ADT Study enrolled 180 men with metastatic hormone-sensitive prostate cancer in mainland China TOKYO , March 13, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced positive topline results from the Phase 3 China ARCHES... Read More

NEW YORK & BOTHELL, Wash. / Mar 13, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion. The Boards of... Read More

NEW YORK / Mar 10, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults. In its pivotal Phase 3 study, ZAVZPRET was statistically superior to placebo on the co-primary endpoints of... Read More

NEW YORK / Feb 28, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that available data is adequate to support the safety and effectiveness of its respiratory syncytial virus (RSV) bivalent vaccine candidate PF-06928316 or RSVpreF. The Committee voted 7 to 4 on safety and 7 to 4 on... Read More

NEW YORK / Feb 27, 2023 / Business Wire / Pfizer Inc . (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Angela Hwang, Chief Commercial Officer, President, Global Biopharmaceutical Business; Rodrigo Puga, U.S. Commercial and Global Business Lead for Internal Medicine; and Annaliesa Anderson, Senior Vice President and Chief Scientific Officer, Vaccine Research and... Read More

NEW YORK / Feb 22, 2023 / Business Wire / Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the company’s Biologics License Application (BLA) for elranatamab, an investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody (BsAb), for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). Priority Review is... Read More

NEW YORK / Feb 21, 2023 / Business Wire / Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for its respiratory syncytial virus (RSV) vaccine candidate PF-06928316 or RSVpreF for the prevention of medically attended lower respiratory tract illness (MA-LRTI) and severe MA-LRTI caused by RSV in infants from birth up to six... Read More

NEW YORK / Feb 16, 2023 / Business Wire / Pfizer (NYSE: PFE) announced today positive results from the Phase 3 TALAPRO-2 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® (enzalutamide), demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI in men with... Read More

NEW YORK / Feb 16, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced publication of results in The Lancet Neurology from the Phase 3 pivotal clinical trial of zavegepant, an investigational calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine. The study met its co-primary endpoints, showing that a single 10 mg dose of zavegepant was more effective than... Read More

NEW YORK / Feb 10, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved its supplemental New Drug Application (sNDA) for CIBINQO ® (abrocitinib), expanding its indication to include adolescents (12 to <18 years) with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug... Read More

NEW YORK / Feb 09, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Andy Schmeltz, SVP Commercial Strategy & Innovation, and Navin Katyal, U.S. Commercial & Global Business Lead for mRNA Portfolio at the SVB Securities Global Biopharma Conference on Thursday, February 16, 2023 at 10:00 a.m. Eastern Standard Time. To listen to the webcast,... Read More

Full-Year 2022 Revenues of $100.3 Billion, An All-Time High for Pfizer, Reflecting 30% Operational Growth Excluding Contributions from Paxlovid and Comirnaty (1) , Revenues Grew 2% Operationally Strong Fourth-Quarter 2022 Revenues of $24.3 Billion, Reflecting 13% Operational Growth Excluding Contributions from Paxlovid and Comirnaty (1) , Revenues Grew 5% Operationally Full-Year 2022 Reported Diluted EPS (2) of $5.47, Up 42%... Read More

Products offered on a not-for-profit basis to the 45 lower-income countries now include the full portfolio for which Pfizer has global rights. Expands on the initial offering of all patented medicines and vaccines available in the U.S. or EU to now include off-patent medicines, bringing total offering from 23 to around 500 products. Builds on already delivered medicines and vaccines along with medical training and supply... Read More

If approved, the vaccine would provide the broadest serotype coverage of any pneumococcal conjugate vaccine in infants and children, and have the potential to help protect against more of the clinically significant remaining burden of disease Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a supplemental Biologics License Application (sBLA) for its... Read More

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 3:00 p.m. Pacific Standard Time. To listen to the webcast, visit our web site at www.pfizer.com/investors . Information on accessing and registering for the webcast will be available... Read More

Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 3 BENEGENE-2 study ( NCT03861273 ) evaluating fidanacogene elaparvovec, an investigational gene therapy, for the treatment of adult males with moderately severe to severe hemophilia B. The BENEGENE-2 study met its primary endpoint of non-inferiority and superiority in the annualized bleeding rate (ABR) of total bleeds post-fidanacogene... Read More

If approved, the vaccine could help simplify the meningococcal vaccination schedule and provide the broadest serogroup coverage of any meningococcal vaccine Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for its investigational pentavalent meningococcal vaccine candidate (MenABCWY). Pfizer submitted MenABCWY for the prevention... Read More

Filings based on two Phase 3 trials demonstrating significant clinical remission versus placebo and safety profile consistent with previous studies Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for etrasimod for individuals living with moderately-to-severely active ulcerative colitis (UC). The FDA’s decision is expected in the... Read More

Data showed high objective response rate of 61% in RRMM patients with no prior BCMA-targeted treatment, with 84% probability of maintaining the response at nine months Results showed early and deep responses, and a manageable safety profile for elranatamab in heavily pretreated patients with advanced multiple myeloma NEW YORK--( BUSINESS WIRE )-- Pfizer Inc. (NYSE:PFE) today announced 10.4 month follow-up data from the... Read More

Bivalent vaccine authorized as third 3-µg dose in the three-dose primary series Consistent COVID-19 hospitalization rates in this age group coupled with an overall surge in respiratory illnesses among children under 5 in the United States creates urgent need to make updated COVID-19 vaccines available Doses to ship immediately upon recommendation by CDC NEW YORK and MAINZ, GERMANY, DECEMBER 8, 2022 — Pfizer Inc. (NYSE: PFE)... Read More

If approved, RSVpreF would help address the substantial burden of RSV disease in individuals 60 years of age or older NEW YORK--( BUSINESS WIRE )-- Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a Biologics License Application (BLA) for its respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or RSVpreF, as submitted for the prevention of... Read More

Agreement aims to advance discovery and development of novel papain-like protease (PLpro) inhibitors and potentially introduce a new class of oral antivirals in the fight against COVID-19 Expands Pfizer’s innovative anti-infective pipeline, complementing the company’s existing portfolio of COVID-19 products NEW YORK & CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Pfizer Inc. (NYSE: PFE) and Clear Creek Bio, Inc. today announced a... Read More

Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule Higher antibody levels were observed in the three-dose vaccination schedule versus the two-dose vaccination schedule, further validating the use of this schedule in the ongoing Phase 3 study There were no safety concerns observed in this six-month observational follow up New York &... Read More

NEW YORK and MAINZ, GERMANY, NOVEMBER 16, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a Phase 1 study to evaluate the safety, tolerability and immunogenicity of a next generation COVID-19 vaccine candidate that aims to enhance SARS-CoV-2 T cell responses and potentially broaden protection against COVID-19. This candidate, BNT162b4, is composed of a T cell... Read More